Optimizing Biosimilars Operations with SAP S/4HANA Cloud Private Edition

As a leading manufacturer of biosimilars, which are close copies of expensive drugs made by living organisms, this client is at the forefront of biotechnology. It’s helping to reduce healthcare costs and improve patient access to vital therapies for diseases from multiple sclerosis to blood disorders.  

To support its mission and scale operations efficiently, the company adopted SAP S/4HANA Cloud Private Edition. The key objectives were to safeguard the deployment, ensure adoption of best practices, enhance operational efficiency, and optimize system security and performance. 

To achieve these goals, the client leveraged SAP ActiveAttention services, enabling quality assurance through project-quality gate checks, design evaluation, gap validation, and custom-code improvements. The integrated SAP landscape included SAP Enable Now for user adoption, SAP Analytics Cloud and SAP Datasphere for analytics, and SAP Signavio for process management. Pharmaceutical-specific testing and digital signatures were managed using SAP Solution Manager and SAP IT Service Management, ensuring compliance and reliability. 

By revamping biosimilars operations with SAP, the client saw better planning and resource allocation during implementation, improved operational efficiency through maximized use of SAP functionalities, and increased adoption of innovative solutions across teams. Furthermore, by minimizing customization and standardizing processes, the client strengthened compliance, optimized system performance, and fostered continuous efficiency improvements.  

The project established a foundation for sustained business transformation, empowering teams to leverage SAP solutions effectively while maintaining technical security and high performance. 

DOWNLOAD THE CASE STUDY BELOW. 

This case study was provided by SAP for value-added resellers like Crescense. Contact our team for more information about optimizing biosimilars operations with SAP.